Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 6/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6167902 | 0.87 | HDAC2 (0.64) | KLK7HDAC2MEN1KMT2APARP1 | |
| SCHEMBL7801726 | 0.87 | HDAC2 (0.64) | KLK7HDAC2MEN1KMT2APARP1 | |
| SCHEMBL11089899 | 0.85 | PARP1 (0.68) | KLK7HDAC2MEN1KMT2APARP1 | |
| SCHEMBL7800401 | 0.85 | ALDH1A1 (0.55) | KLK7MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL7800402 | 0.85 | ALDH1A1 (0.55) | KLK7MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL29006058 | 0.83 | HDAC2 (0.57) | KLK7HDAC2MEN1KMT2APARP1 | |
| SCHEMBL13345388 | 0.83 | HDAC2 (0.57) | KLK7HDAC2MEN1KMT2APARP1 | |
| SCHEMBL7797349 | 0.83 | KLK7 (0.61) | KLK7MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7815830 | 0.82 | ALDH1A1 (0.59) | KLK7MEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL13345389 | 0.81 | HDAC2 (0.69) | KLK7HDAC2PARP1PARP10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044107-A1 | Inhibitors of JMJD2C as Anticancer Agents | THE J. DAVID GLADSTONE INSTITUTES | 2017-02-16 | — | — | US | disclosed |
| WO-2005039565-A1 | COMBINATIONS OF COX AND VASOPRESSIN INHIBITORS FOR THE TREATMENT OF DISMENORRHEA | PFIZER LIMITED (GB) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044107-A1 | Inhibitors of JMJD2C as Anticancer Agents | KDM2A, KDM1B, KDM5C | KLK7 1651/4885HDAC2 87/4885MEN1 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.